Second phase III, randomised, multicentre, double-blind, placebo-controlled trial of HMPL-004 induction therapy in patients with mild-to-moderate ulcerative colitis
Latest Information Update: 03 May 2013
Price :
$35 *
At a glance
- Drugs HMPL 004 (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms NATRUL-5
- 03 May 2013 New trial record